Hepatorenal syndrome: new insights about treatment (part III)
https://doi.org/10.21886/2712-8156-2022-3-4-32-39
Abstract
Hepatorenal syndrome is a common and serious complication in cirrhotic patients, leading to significant morbidity and mortality. Although pharmacological treatments have shown mortality benefit, the ideal hepatorenal syndrome treatment option is liver transplantation with or without simultaneous kidney transplantation. Further research is required to optimize pharmacologic and nonpharmacologic approaches to treatment. An analysis of literature reviews, clinical studies, experimental research, clinical recommendations from PubMed / Medline and ELIBRARY databases was carried out for 7 keywords according to the review topic.
About the Authors
E. S. Krutikov
Medical Academy named after S. I. Georgievsky of Vernadsky CFU
Russian Federation
Russian Federation
Evgeniy S. Krutikov, Dr. Sci. (Med.), Professor, Head of Department of Propedeutics of Internal
Simferopol
A. N. Vostrikova
Medical Academy named after S. I. Georgievsky of Vernadsky CFU
Russian Federation
Russian Federation
Aleksandra N. Vostrikova, student, Department of Internal Medicine No. 1
Simferopol
S. N. Krutikov
Medical Academy named after S. I. Georgievsky of Vernadsky CFU
Russian Federation
Russian Federation
Segey N. Krutikov, Dr. Sci. (Med.), Professor, Department of Internal Medicine No. 2
Simferopol
References
1. Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet. 2003;362(9398):1819-27. doi: 10.1016/S0140-6736(03)14903-3
2. El-Naggar MM, Khalil EA, El-Daker MAM, Salama MF. Bacterial DNA and its consequences in patients with cirrhosis and culture-negative, non-neutrocytic ascites. J Med Microbiol. 2008;57(Pt 12):1533-1538. doi: 10.1099/jmm.0.2008/001867-0
3. Solé C, Solà E, Morales-Ruiz M, Fernàndez G, Huelin P, Graupera I, et al. Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis. Sci Rep. 2016;6:32341. doi: 10.1038/srep32341
4. Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59(1):105-10. doi: 10.1136/gut.2009.180570
5. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology. 1999;29(2):334-9. doi: 10.1002/hep.510290203
6. Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers. 2018;4(1):23. doi: 10.1038/s41572-018-0022-7. Erratum in: Nat Rev Dis Primers. 2018;4(1):33. PMID: 30213943
7. Lange CM. Systemic inflammation in hepatorenal syndrome - A target for novel treatment strategies? Liver Int. 2019;39(7):1199-1201. doi: 10.1111/liv.14057
8. Tujios SR, Hynan LS, Vazquez MA, Larson AM, Seremba E, Sanders CM, et al. Risk factors and outcomes of acute kidney injury in patients with acute liver failure. Clin Gastroenterol Hepatol. 2015;13(2):352-9. doi: 10.1016/j.cgh.2014.07.011
9. Huelin P, Piano S, Solà E, Stanco M, Solé C, Moreira R, et al. Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acuteon-Chronic Liver Failure. Clin Gastroenterol Hepatol. 2017;15(3):438-445.e5. doi: 10.1016/j.cgh.2016.09.156
10. Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71(4):811-822. doi: 10.1016/j.jhep.2019.07.002
11. Осипенко М.Ф., Волошина Н.Б., Шайде Н.Л. Патология почек при циррозе печени. Эффективная фармакотерапия. 2020;1(16):58–61. doi: 10.33978/2307-3586-2020-16-1-58-61
12. Саварина В.А., Мицура В.М., Скуратов А.Г., Мартемьянова Л.А. Проблемы диагностики гепаторенального синдрома в практике клинициста и патологоанатома. Проблемы Здоровья и Экологии. 2020;65(3):49–55. eLIBRARY ID:44229771
13. Gifford FJ, Morling JR, Fallowfield JA. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Aliment Pharmacol Ther. 2017;45(5):593-603. doi: 10.1111/apt.13912
14. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64(4):531-7. doi: 10.1136/gutjnl-2014-308874
15. Chancharoenthana W, Leelahavanichkul A. Acute kidney injury spectrum in patients with chronic liver disease: Where do we stand? World J Gastroenterol. 2019;25(28):3684-3703. doi: 10.3748/wjg.v25.i28.3684
16. Wong F. Acute kidney injury in liver cirrhosis: new definition and application. Clin Mol Hepatol. 2016;22(4):415-422. doi: 10.3350/cmh.2016.0056
17. Wong F. Diagnosing and treating renal disease in cirrhotic patients. Minerva Gastroenterol Dietol. 2016;62(3):253-66. PMID: 27096702
18. Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146(7):1680-90.e1. doi: 10.1053/j.gastro. 2014.03.005
19. Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Dig Liver Dis. 2017;49(1):3-10. doi: 10.1016/j.dld.2016.09.013
20. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. doi: 10.1016/j.jhep.2018.03.024. Erratum in: J Hepatol. 2018;69(5):1207. PMID: 29653741
21. Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58(5):1836-46. doi: 10.1002/hep.26338
22. Wong F, Jepsen P, Watson H, Vilstrup H. Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. Liver Int. 2018;38(10):1785-1792. doi: 10.1111/liv.13738
23. Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol. 2013;11(2):123-30.e1. doi: 10.1016/j.cgh.2012.11.007
24. Fernández J, Angeli P, Trebicka J, Merli M, Gustot T, Alessandria C, et al. Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. Clin Gastroenterol Hepatol. 2020;18(4):963-973.e14. doi: 10.1016/j.cgh.2019.07.055
25. Leão GS, John Neto G, Jotz RF, Mattos AA, Mattos ÂZ. Albumin for cirrhotic patients with extraperitoneal infections: A meta-analysis. J Gastroenterol Hepatol. 2019;34(12):2071-2076. doi: 10.1111/jgh.14791
26. Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391(10138):2417-2429. doi: 10.1016/S0140-6736(18)30840-7
27. Глумчер Ф.С. Возможности применения альбумина в терапии критических состояний: современное состояние проблемы. Медицина неотложных состояний. 2014;2(57):65-73. eLIBRARY ID:21692096
28. China L, Skene SS, Bennett K, Shabir Z, Hamilton R, Bevan S, et al. ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial. BMJ Open. 2018;8(10):e023754. doi: 10.1136/bmjopen-2018-023754
29. Kamal F, Khan MA, Khan Z, Cholankeril G, Hammad TA, Lee WM, et al. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(10):1109-1117. doi: 10.1097/MEG.0000000000000940
30. Сливка Н.А. Сравнительная оценка эффективности вазопрессоров при гепаторенальном синдроме. Universum: медицина и фармакология. 2019;6(61):4-7. eLIBRARY ID:39168357
31. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-181. doi: 10.1016/j.jhep.2018.03.018
32. Bhutta AQ, Garcia-Tsao G, Reddy KR, Tandon P, Wong F, O'Leary JG, et al. Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther. 2018;47(1):78-85. doi: 10.1111/apt.14366
33. Пиманов С.И., Макаренко Е.В. Лечение декомпенсированного цирроза печени. Часть II. Гепаторенальный синдром. Гастроэнтерология. Хирургия. Интенсивная терапия. Consilium Medicum. 2019;1:36–41. doi: 10.26442/26583739.2019.1.190295
34. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417. doi: 10.1016/j.jhep.2010.05.004
35. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279-90. doi: 10.1056/NEJMra0809139. Erratum in: N Engl J Med. 2011;364(4):389. PMID: 19776409
36. Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, et al. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology. 2016;150(7):1579-1589.e2. doi: 10.1053/j.gastro.2016.02.026
37. Rodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol. 2014;60(5):955-61. doi: 10.1016/j.jhep.2013.12.032. Erratum in: J Hepatol. 2014;61(2):456. PMID: 24447876
38. Gupta K, Rani P, Rohatgi A, Verma M, Handa S, Dalal K, et al. Noradrenaline for reverting hepatorenal syndrome: a prospective, observational, single-center study. Clin Exp Gastroenterol. 2018;11:317-324. doi: 10.2147/CEG.S153858
39. Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study. Indian J Gastroenterol. 2018;37(5):424-429. doi: 10.1007/s12664-018-0876-3
40. Israelsen M, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017;9(9):CD011532. doi: 10.1002/14651858.CD011532.pub2
41. Nassar Junior AP, Farias AQ, D' Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One. 2014;9(9):e107466. doi: 10.1371/journal.pone.0107466
42. Mattos ÂZ, Mattos AA, Ribeiro RA. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. Eur J Gastroenterol Hepatol. 2016;28(3):345-51. doi: 10.1097/MEG.0000000000000537
43. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310-8. doi: 10.1136/gut.2006.107789
44. Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology. 2014;146(1):138-146.e5. doi: 10.1053/j.gastro.2013.09.031
45. Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA. 2013;310(10):1033-41. doi: 10.1001/jama.2013.276300
46. Busk TM, Bendtsen F, Henriksen JH, Fuglsang S, Clemmesen JO, Larsen FS, et al. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis. Dig Liver Dis. 2017;49(12):1353-1359. doi: 10.1016/j.dld.2017.06.011
47. Ascha M, Abuqayyas S, Hanouneh I, Alkukhun L, Sands M, Dweik RA, et al. Predictors of mortality after transjugular portosystemic shunt. World J Hepatol. 2016;8(11):520-9. doi: 10.4254/wjh.v8.i11.520
48. Lang M, Lang AL, Tsui BQ, Wang W, Erly BK, Shen B, et al. Renal-function change after transjugular intra-hepatic portosystemic shunt placement and its relationship with survival: a single-center experience. Gastroenterol Rep (Oxf). 2020;9(4):306-312. doi: 10.1093/gastro/goaa081
49. Song T, Rössle M, He F, Liu F, Guo X, Qi X. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. Dig Liver Dis. 2018;50(4):323-330. doi: 10.1016/j.dld.2018.01.123
50. Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123(6):1839-47. doi: 10.1053/gast.2002.37073
51. Gilg S, Sparrelid E, Saraste L, Nowak G, Wahlin S, Strömberg C, et al. The molecular adsorbent recirculating system in posthepatectomy liver failure: Results from a prospective phase I study. Hepatol Commun. 2018;2(4):445-454. doi: 10.1002/hep4.1167
52. Bahirwani R, Campbell MS, Siropaides T, Markmann J, Olthoff K, Shaked A, et al. Transplantation: impact of pretransplant renal insufficiency. Liver Transpl. 2008;14(5):665-71. doi: 10.1002/lt.21367
53. Lenz K, Buder R, Kapun L, Voglmayr M. Treatment and management of ascites and hepatorenal syndrome: an update. Therap Adv Gastroenterol. 2015;8(2):83-100. doi: 10.1177/1756283X14564673
54. Wadei HM. Patients with Hepatorenal Syndrome Should Be Dialyzed? CON. Kidney360. 2020;2(3):410-412. doi: 10.34067/KID.0006872020
55. Mindikoglu AL, Pappas SC. New Developments in Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018;16(2):162-177.e1. doi: 10.1016/j.cgh.2017.05.041. Erratum in: Clin Gastroenterol Hepatol. 2018;16(6):988. PMID: 28602971; PMCID: PMC5831376
56. Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020;370:m2687. doi: 10.1136/bmj.m2687
57. Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55(2):315-21. doi: 10.1016/j.jhep.2010.11.020
58. Nazar A, Pereira GH, Guevara M, Martín-Llahi M, Pepin MN, Marinelli M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51(1):219-26. doi: 10.1002/hep.23283
59. Бакулин И.Г., Варламичева А.А. Асцит, спонтанный бактериальный перитонит, гепаторенальный синдром: что общего в диагностике и лечении? Терапевтический архив. 2015;87(4):77-83. doi: 10.17116/terarkh201587477-83
Review
For citations:
Krutikov E.S., Vostrikova A.N., Krutikov S.N. Hepatorenal syndrome: new insights about treatment (part III). South Russian Journal of Therapeutic Practice. 2022;3(4):32-39. (In Russ.) https://doi.org/10.21886/2712-8156-2022-3-4-32-39
Views:
2626
Email this article 